Sage Menogen tablets seized; firm settles with Estratest manufacturer Solvay.
Executive Summary
SAGE MENOGEN ESTERIFIED ESTROGENS/METHYLTESTOSTERONE GENERIC TABLETS SEIZED Jan. 9, following a Jan. 5 request for seizure of two lots (approximately 1,061 bottles) of Menogen by Florida U.S. Attorney Thomas Scott. The request for seizure states that the product had been shipped in interstate commerce although "no approvals of applications filed [with FDA] are in effect for such drugs." In addition, as part of a Dec. 8 settlement with Solvay Pharmaceuticals, Sage is enjoined from further manufacturing or marketing of Menogen. Solvay markets Estratest (esterified estrogens and methyltestosterone).
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth